



Transdermal Lidocaine for Perioperative Pain: a Systematic Review of the Literature

Jordan Smoker¹ · Alexa Cohen² · Mohammad R. Rasouli³ · Eric S. Schwenk¹

Published online: 14 November 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Purpose of Review The purpose of this review is to provide a summary of the perioperative studies that have examined transdermal lidocaine (lidocaine patch) as an analgesic and put the evidence in context of the likely overall benefit of transdermal lidocaine in the perioperative period.

Recent Findings Several randomized controlled trials have been published in the past 4 years that concluded transdermal lidocaine can reduce acute pain associated with laparoscopic trocar or cannula insertion.

Summary Transdermal lidocaine may reduce short-term pain after surgery in selected surgery types and has a low risk of toxicity but its overall clinical utility in the perioperative setting is questionable. Transdermal lidocaine does not consistently reduce opioid consumption after surgery and has not been shown to improve patient function.

Keywords Transdermal lidocaine · Lidocaine patch · Perioperative analgesia · Multimodal analgesia · Local anesthetics · Opioid epidemic

Introduction

Recent data have shown that the risk of taking chronic opioids after surgery increases after about 5 days of postoperative opioid therapy [1]. Alternatives to opioids are desirable, especially those with few or no systemic adverse drug effects (ADEs), and transdermal lidocaine is one such perioperative multimodal agent that has been used clinically for decades. Lidocaine as a local anesthetic was first described in the 1940s [2]. Although transdermal lidocaine has mostly been studied in neuropathic pain, where it is one of only two approved topical agents [3], it

has a role in the management of postoperative pain in some patients based on its cost, availability, and safety. Lidocaine is an amide local anesthetic whose mechanism of action is blockade of voltage-gated sodium channels and because of its relatively low potency compared to other local anesthetics, it is less toxic at clinically relevant doses than others, such as bupivacaine and ropivacaine [4]. When used in recommended doses, transdermal lidocaine has minimal systemic absorption and has proven efficacy and safety in postherpetic neuralgia and is recommended as a first-line treatment [5••]. During the perioperative period when gastrointestinal absorption may be altered and oral medications are not first-line agents immediately after surgery, parenteral and transdermal formulations may be preferred. Because of the publication of several recent studies, a review focusing on the analgesic benefits of perioperative transdermal lidocaine is warranted. We therefore performed a systematic review of the literature to determine the overall benefit of transdermal lidocaine on perioperative pain.

This article is part of the Topical Collection on *Other Pain*

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s11916-019-0830-9>) contains supplementary material, which is available to authorized users.

✉ Eric S. Schwenk
Eric.Schwenk@jefferson.edu

¹ Department of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA

² Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

³ Department of Anesthesiology, Perioperative and Pain Medicine, Division of Pain Medicine, Stanford University Hospital, Palo Alto, CA, USA

Methods

Literature Search Details

We conducted the review protocol using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses

(PRISMA) guidelines (see supplemental file) [6]. During the month of December 2018, we conducted searches of PubMed and Scopus databases looking for randomized controlled trials (RCTs) that studied the efficacy of lidocaine patch in patients undergoing surgery. The last date searched was December 19, 2018. There were no date limitations placed on the searches in either database. We used the following search protocol in PubMed: (“lidocaine patch”[All Fields] OR “transdermal lidocaine”[All Fields]) AND (“postoperative pain”[All Fields] OR “acute pain”[All Fields]) and limited results to the English language.

Our search protocol for Scopus included the following: (ALL (“lidocaine patch”) OR ALL (“transdermal lidocaine”) AND ALL (“postoperative pain”) OR ALL (“Acute pain”)) AND (LIMIT-TO (DOCTYPE, “ar”)) AND (LIMIT-TO (LANGUAGE, “English”)).

Inclusion Criteria

Studies involving patients who were undergoing surgery and were given either transdermal lidocaine, placebo, or active comparator in the perioperative period with the primary endpoint of improvement in pain were included in the analysis. Only RCTs were included.

Exclusion Criteria

Studies that were prospective but did not include a placebo group or comparative treatment group were excluded, as were studies in which patients were not randomized. Studies that were not conducted in adults (> 17 years of age), as well as studies conducted in animals, were not included. Finally, studies that did not provide an assessment of pain control, those that studied patients who did not have surgery, and those that studied patients outside of the perioperative period were all excluded.

Review Protocol, Evidence Grading, and Assessment of Bias

Evidence quality was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach (Table 1) [14]. Using this approach, studies are classified as high, moderate, low, or very low quality of evidence.

All articles were first reviewed independently by J.S. and A.C. and assessed for inclusion in the review. If the determination could not be made from reading the article title, the abstract was reviewed, and if ambiguity remained after that, the full article was subsequently downloaded and reviewed. Discrepancies were resolved by discussion between J.S. and A.C., with M.R. having the tie-breaking vote if needed.

The risks of bias related to sequence generation, allocation concealment, blinding of personnel and participants, blinding

of outcome assessment, and handling of incomplete outcome data were evaluated using the Cochrane Collaboration’s tool for assessing bias in randomized trials [15].

Results

Included Studies

Initial search of the literature yielded 265 articles (Fig. 1). Because of the overlap between PubMed and Scopus databases, there were four duplicates. Reasons for exclusion are shown in Fig. 1. The most common reasons for exclusion were that transdermal lidocaine was not studied ($n = 151$), and that studies were not perioperative studies ($n = 47$). A total of seven studies were included in the final review. Meta-analysis was deemed inappropriate given the heterogeneity between studies and endpoints.

Primary Outcome

A total of seven RCTs that studied the use of transdermal lidocaine in the setting of the perioperative period were included in the review (Table 1). All included studies compared transdermal lidocaine to placebo, with two studies also having an IV lidocaine comparison group [9, 11]. The type of surgery was not homogenous and included robotic cardiac valve surgery, laparoscopic gynecological surgery, gynecological surgery via laparotomy, laparoscopic appendectomy, “elective operations,” and radical prostatectomy. The primary outcome for four studies was the mean visual analog scale (VAS) pain rating [7, 8, 11, 12]. Another study’s primary outcome was the pain disability index [10•]. A single study used the 4-point categorical verbal rating scale [9] and in the last study, the primary outcome was pain rating on the 11-point verbal rating scale (VRS) [13].

Overall, five out of the seven studies analyzed reported lower pain ratings in the lidocaine group compared to placebo [7, 9, 11–13]. Three out of the four studies that used VAS as primary endpoint reported that transdermal lidocaine decreased postoperative pain ratings at rest, which remained reduced for 6 h [12], 24 h [7], and 72 h [11], although the pain ratings with movement were no different in two of them [7, 12]. The remaining VAS study found no difference [8]. The study that used pain disability index found no improvement in acute or chronic pain with transdermal lidocaine [10•]. The study whose primary outcome was the 4-point scale reported that the incidence of cannula-induced pain was lowest in the transdermal lidocaine group compared to both placebo and intravenous lidocaine groups [9]. In the single study that used the 11-point VRS, pain at rest for up to 12 h and with coughing for up to 24 h was reduced in the transdermal lidocaine group [13].


Table 1 Pain outcomes

First author and year	Surgical procedure	Sample size	Study groups	Primary outcome	Primary outcome in lidocaine group	Primary outcome in control group	Primary outcome positive? (yes/no)	Pain ratings in other active treatment group	Opioid consumption	Evidence quality
Lau et al. [7]	Laparotomy with midline incision	28	Group 1: transdermal lidocaine Group 2: placebo	VAS pain rating	Mean reduction in post-operative pain: At rest 3.16 On movement 5.53 Total T-VAS (umbilical trocar): At rest 2.31 In ambulation 2.04 Total RLQ-VAS (right lower quadrant): At rest 2.26 In ambulation 2.46 Total S-VAS At rest 0.63 In ambulation 0.43	Mean reduction in post-operative pain: At rest 3.98 On movement 5.81 Total T-VAS: At rest 2.46 Total RLQ-VAS: At rest 2.23 In ambulation 2.40 Total S-VAS: At rest 0.81 In ambulation 0.48	At rest: Yes On movement: No No	N/A	No difference between groups	Moderate
Lee et al. [8]	Laparoscopic appendectomy	40	Group 1: transdermal lidocaine Group 2: placebo	VAS pain rating					Lower IV meperidine consumption in group 1 (0.10 vs. 0.25 mg); uncertain clinical significance	Low Comments: no flow diagram provided; unclear if patients were excluded
Hong et al. [9]	Elective surgery	126	Group 1: transdermal lidocaine, normal saline, and propofol Group 2: placebo, normal saline, propofol Group 3: placebo, IV lidocaine, propofol	VRS pain rating (4-point Likert scale)	Group 1 Cannula pain, N (%): None 20 (52.6) Mild 10 (26.3) Moderate 8 (21.1) Severe 0 Injection pain, N (%): None 19 (50.0) Mild 11 (28.9) Moderate 8 (21.1) Severe 0 (0) Recall of injection pain, N (%): None 7 (18.9) Mild 5 (13.5) Moderate 19 (51.4) Severe 6 (16.2) Recall of injection pain, N (%): None 23 (60.5) Mild 13 (34.2) Moderate 2 (5.3) Severe 0 (0) Pain disability index, mean (SD): Baseline: 3.3 (6.8) POD 7: 26 (17) POD 30: 12 (14) POD 90: 3.2 (7.8) POD 180: 1.7 (6.4)	Group 2 Cannula pain, N (%): None 2 (5.4) Mild 20 (54.1) Moderate 11 (29.7) Severe 4 (10.8) Injection pain, N (%): None 7 (18.9) Mild 5 (13.5) Moderate 19 (51.4) Severe 6 (16.2) Recall of injection pain, N (%): None 14 (37.8) Mild 11 (29.7) Moderate 10 (27.0) Severe 2 (5.4) Pain disability index, mean (SD): Baseline: 3.0 (7.7) POD 7: 30 (19) POD 30: 30 (19) POD 90: 5.0 (13.3) POD 180: 4.8 (15.5)	Cannula pain: Yes Injection pain: No Recall of injection pain: No	Group 3 Cannula pain, N (%): None 2 (5.3) Mild 19 (50.0) Moderate 12 (31.6) Severe 5 (13.2) Injection pain, N (%): None 16 (42.1) Mild 17 (44.7) Moderate 5 (13.2) Severe 0 (0) Recall of injection pain, N (%): None 19 (50.0) Mild 17 (44.7) Moderate 2 (5.3) Severe 0 (0)	Not reported	Low Comments: no flow diagram provided; unclear if any patients were screened and excluded
Vrooman et al. [10]	Robotic cardiac valve surgery, mitral or aortic valve repair, right-sided thoracotomy	78	Group 1: transdermal lidocaine Group 2: placebo	Pain disability index			No	N/A	No difference between groups	Moderate

Table 1 (continued)

First author and year	Surgical procedure	Sample size	Study groups	Primary outcome	Primary outcome in lidocaine group	Primary outcome in control group	Primary outcome positive? (yes/no)	Pain ratings in other active treatment group	Opioid consumption	Evidence quality
Elhafiz et al. [11]	Laparoscopic colorectal surgery	27	Group 1: placebo Group 2: IV lidocaine infusion Group 3: transdermal lidocaine	VAS pain rating	Group 3, VAS at rest - (post-op hour): 3.8 (1), 3.3 (4), 2.8 (12), 2.6 (24), 2.4 (36), 2.1 (48), 1.8 (60), 1.3 (72), 1.2 (84), 1.4 (96), 1.2 (108), 1.1 (120) VAS during coughing transdermal lidocaine (post-op hour): 4.9 (1), 4.6 (4), 3.9 (12), 3.2 (24), 3.5 (36), 2.9 (48), 2.6 (60), 2.8 (72), 2.3 (84), 1.9 (96), 1.6 (108), 1.3 (120)	Group 1, VAS at rest (post-op hour): 5.3 (1), 4.9 (4), 4.7 (12), 4.1 (24), 3.9 (36), 3.5 (48), 2.9 (60), 2.1 (72), 1.7 (84), 1.4 (96), 1.2 (108), 1.3 (120) VAS during coughing (post-op hour): 6.2 (1), 5.8 (4), 5.4 (12), 5.2 (24), 4.6 (36), 3.8 (48), 3.9 (60), 3.4 (72), 2.7 (84), 2.4 (96), 1.9 (108), 1.8 (120)	Yes	Group 2, VAS at rest (post-op hour): 3.6 (1), 3.1 (4), 2.9 (12), 2.7 (24), 2.2 (36), 1.9 (48), 1.5 (60), 1.2 (72), 1.5 (84), 1.3 (96), 1.5 (108), 1.2 (120) VAS during coughing (post-op hour): 4.5 (1), 4.3 (4), 3.7 (12), 3.5 (24), 3.1 (36), 2.5 (48), 2.9 (60), 2.3 (72), 1.9 (84), 2.1 (96), 1.8 (108), 1.5 (120)	IV morphine consumption reduced in Groups 2 and 3; no difference between Groups 2 and 3	Very low Comments: high risk of bias in 3 areas; no flow diagram provided; unclear if any patients were screened and excluded
Kwon et al. [12]	Laparoscopic gynecological surgery	40	Group 1: transdermal lidocaine Group 2: placebo	VAS pain rating	VAS (post-op hour): 4.2 (1), 1.9 (6), 1.8 (12), 1.9 (24), 1.7 (36)	VAS (post-op hour): 6.5 (1), 4.3 (6), 3.8 (12), 2.2 (24), 1.8 (36)	Yes	N/A	No difference between groups	Moderate
Habib et al. [13]	Radical retropubic prostatectomy	70	Group 1: transdermal lidocaine Group 2: placebo	VRS pain rating	VRS at rest (post-op hour): 4.0 (0), 4.5 (0.5), 3.9 (1), 3.5 (1.5), 3.4 (2), 2.5 (6), 1.5 (12), 1.8 (24) VRS coughing (post-op hour): 5.5 (0), 5.5 (0.5), 5.5 (1), 5.4 (1.5), 5.4 (2), 4.8 (6), 3.7 (12), 3.5 (24)	VRS at rest (post-op hour): 5.5 (0), 6.0 (0.5), 5.5 (1), 5.6 (1.5), 4.6 (2), 3 (6), 2.2 (12), 1.8 (24) VRS coughing (post-op hour): 7.8 (0), 7.8 (0.5), 7.2 (1), 7.1 (1.5), 6.9 (2), 6.1 (6), 5.5 (12), 4.5 (24)	Yes	N/A	No difference between groups	Low Comments: no flow diagram provided; unclear if any patients were screened and excluded

Fig. 1 Study flow diagram



Secondary Outcomes

All but one study by Hong et al. [9] reported opioid consumption in the study groups. In four studies, there was no difference in opioid consumption between treatment and placebo groups [7, 10•, 12, 13] and opioid consumption was not reported in another [9]. Meperidine use was reduced a small amount of uncertain clinical significance in the transdermal lidocaine group in the study by Lee et al. [8] and in the study by Elhafz et al. [11] opioid use was reduced the same amount by both transdermal lidocaine and IV lidocaine.

Although patient satisfaction is typically an important secondary outcome, only two of the studies reported on this. Vrooman et al. [10•] reported no difference between transdermal lidocaine group and placebo, while Habib et al. [13] found that patients who received transdermal lidocaine rated overall pain control quality better and reported less interference with walking, breathing, and mood.

Study Quality and Consistency and Assessment of Bias

The studies reviewed ranged from very low to moderate quality according to the GRADE recommendations for rating study quality (Table 1) [14]. Heterogeneity in end points as well as study protocols was a problem throughout the literature. For example, some studies examined pain at rest and with movement [7, 8, 11, 13], some reported global pain ratings [10•, 12], and others focused on pain at specific sites [9]. Some studies used the VAS [7, 8, 11, 12] while others used the 11-point VRS [13] or 4-point Likert scale [9] and the final study used a pain disability index [10•]. The dose of lidocaine used in the treatment group varied between studies. Lau et al. [7] used a single lidocaine patch while Lee et al. used two patches on either side of the trocar site [8]. Hong et al. [9] used a single patch that was applied to venous cannulation site and then removed prior to cannulation, while Vrooman et al. [10•] and Kwon et al. [12] used an entire 700-mg lidocaine patch at the surgical site. Habib et al. [13] used a single patch,

the dose of which was unclear, and cut it in half and applied to either side of the wound, and Elhafz et al. [11] used three lidocaine patches. Overall, the studies had a low risk of bias in all areas, with the exception of the study by Elhafz et al. (Tables 2 and 3) [11].

Safety and Adverse Events

None of the seven studies reported any adverse events related to transdermal lidocaine, although none of them were adequately powered for that outcome. Elhafz et al. [11] stated that there were no “adverse events of local anesthetic toxicity,” while patients who received transdermal lidocaine in the study by Lee et al. [8] experienced no nausea, vomiting, erythema, rash, contact dermatitis, hypotension, bradycardia, cardiovascular instability, headache, or dizziness. Vrooman et al. [10] described an equal number of transdermal lidocaine and placebo patients with various adverse events, none of which was attributed to the treatment assignment.

Discussion

This review demonstrates that transdermal lidocaine may provide a modest improvement in pain ratings in the perioperative period but the number of studies was limited and the duration of benefit is limited. Although five out of seven studies showed a decrease in pain ratings with transdermal lidocaine, this reduction was typically only observed at rest and often did not translate to decreased opioid consumption, making the overall clinical benefit questionable.

A previous review in 2015 of transdermal lidocaine for acute and postoperative pain concluded that it did not improve pain, reduce opioid consumption, or reduce length of stay and questioned the overall efficacy of transdermal lidocaine as an analgesic adjunct [16]. Two of the most recently published studies included in our review [8, 9] focused on pain at cannula and trocar sites and were published after that review. One

study found that transdermal lidocaine did not decrease pain at the site of peripheral IV cannula insertion [9], while the other did report a brief but statistically significant decrease in pain at the site of trocar insertion [8]. In the latter study, the overall VAS pain ratings were low at all time points except the initial rating immediately after surgery, so it is not clear that the reported differences would translate to changes in treatment.

In three of the five studies with positive results, transdermal lidocaine decreased pain at the site of either a cannula or trocar [9, 11, 12]. This may represent the most logical use of the patch, which is approved at this time only for use in postherpetic neuralgia [3•], a condition in which the varicella zoster virus may damage sensory nerves and dermatomal pain occurs [5••]. The conceptual basis for lidocaine’s efficacy in postherpetic neuralgia is that neuronal cell injury leads to the development of abnormal sodium channels, which are a target for transdermal lidocaine [5••]. Tissue trauma that occurs in laparoscopic surgery is mostly limited to discrete areas of trocar insertion and a topical treatment like transdermal lidocaine is logical for neuropathic pain in a limited distribution such as this.

It was interesting to note that only two of the seven included studies reported a decrease in opioid consumption in the lidocaine groups. Our interpretation of this finding is that while transdermal lidocaine may have a role in decreasing localized pain for a short period of time, such as during insertion of a cannula or trocar, it does not provide substantial and lasting relief that actually affects analgesic use. It would be easy to dismiss this type of ephemeral relief as unimportant but patient satisfaction remains a key driver of hospital reimbursement [17], with patient perception of pain management a major factor in that overall rating. Seemingly small details, such as pain experienced during brief procedures, may contribute to patient perception of overall pain control. The cost of one lidocaine patch 5% at our institution as of July 2019 is \$2.25, which is relatively inexpensive when considering the potential costs of poor patient satisfaction ratings on surveys such as the Hospital Consumer Assessment of Healthcare

Table 2 Author’s risk of bias judgement

Study first author and year	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (Reporting bias)
Lau et al. [7]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Lee et al. [8]	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low risk
Hong et al. [9]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Vrooman et al. [10•]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Elhafz et al. [11]	Low risk	High risk	High risk	High risk	Unclear risk	Low risk
Kwon et al. [12]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Habib et al. [13]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk

Table 3 Support for the author's risk of bias judgement

Study first author and year	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (Reporting bias)
Lau et al. [7]	<p>"Sequence generation was from a computer-generated random binary number list performed by an anesthesiologist not involved in the study."</p>	<p>"1:1 allocation ratio" "A sealed opaque envelope was used for allocation concealment"</p>	<p>"patients, Acute Pain Team staff, study personnel and the data analyst were blinded to treatment allocation." "lidocaine patch was replaced by a placebo plaster of the same size" "active and placebo plasters were prepared by third-party anesthesiologists" "plaster applications and removal were performed by nurses who were not part of the study team"</p>	<p>"blinded randomized controlled trial"</p>	<p>"All patients received their allocated intervention and none were lost to follow-up. There were no missing data."</p>	<p>"Postoperative pain at rest and on movement at 24 hours were the primary study endpoints"</p>
Lee et al. [8]	<p>"randomized double-blind prospective controlled study"</p>	<p>"patients who underwent laparoscopic appendectomy were randomized into two groups immediately after surgery by an IRB moderator who was blinded to the study"</p>	<p>"randomized double-blind prospective controlled study" "In the control group, indistinguishable patches with the same shape and nature were applied in the same way."</p>	<p>"randomized double-blind prospective controlled study"</p>	<p>Comment: Not explicitly or clearly stated</p>	<p>"pain intensity was assessed with the visual analog scale every 6 hours up to 48 hours after laparoscopic appendectomy."</p>
Hong et al. [9]	<p>"allocated by sealed envelope including computer generated random numbers into three groups"</p>	<p>"allocated by sealed envelope including computer generated random numbers into three groups"</p>	<p>"For the placebo patch, the release liner was not removed and the patch was applied to the same site. Thus, the active patch and the placebo patch were identical in weight, shape, and color."</p>	<p>"anesthesiologists who performed cannulation were not informed whether a 5% lidocaine patch or placebo patch had been used" "presence of emergence delirium was assessed by an investigator blinded to which drug had been administered"</p>	<p>"A total of 126 patients were randomly allocated into three groups. Four patients in Group A, five patients in Group B, and four patients in Group C were excluded because of inappropriate application of active or placebo patch and failure in intravenous cannulation."</p>	<p>"We used a 4-point categorical verbal rating scale (VRS-4) with the words "no pain," "mild pain," "moderate pain," and "severe pain". Patients were asked to assess their pain by rating their intensity of pain during insertion of the cannula."</p>
Vrooman et al. [10]	<p>"Randomization was performed by our Research Pharmacy and was based on computer-generated codes."</p>	<p>"Patients were randomized 1:1"</p>	<p>"All investigators and clinicians were fully blinded to treatment."</p>	<p>"randomized, placebo-controlled, double-blind trial."</p>	<p>"Two patients were withdrawn because they had open-heart surgery instead of the originally scheduled robotic surgery. Analysis was therefore restricted to 39 patients randomized to lidocaine 5% patch and 39 patients randomized to placebo"</p>	<p>"Pain was initially evaluated with a Visual Analog Scale, and subsequently by telephone with a Verbal Response Scale and the Pain Disability Index (our primary outcome) after 1 week, 1 month, 3 months, and 6 months. Global Perceived Effect, a measure of patient satisfaction, was simultaneously recorded."</p>

Table 3 (continued)

Study first author and year	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (Reporting bias)
Elhafz et al. [11]	“Prospective, randomized, controlled study”	“Patients randomly assigned to one of three equal groups, placebo group (group 1), i.v. lidocaine infusion (group 2) and lidocaine patch (group 3).” Comment: no description of how this was carried out	Comment: Not explicitly stated	Comment: Not explicitly stated	Comment: Not explicitly stated	“Data collected were, pain scores (VAS), morphine consumption, return of bowel function, pro-inflammatory cytokines plasma levels and plasma lidocaine level.”
Kwon et al. [12]	“assigned randomly to one of two groups using a computer-generated random number table”	“assigned randomly to one of two groups using a computer-generated random number table”	“study patches were sealed in an opaque envelope labeled with the randomization numbers”	“No person was aware of the group assignment until all the patients had been included and assessments were completed.” “Data were collected by study personnel who were unaware of the patients’ randomization at 1, 6, 12, 24, and 36 hours, postoperatively.”	Comment: Low risk determined from flow diagram of patient distribution displayed in Figure 1.	“The primary outcome measure was the visual analog scale (VAS) score for postoperative wound pain and postoperative pain at rest and during ambulation. The other data collected included the Prince Henry Verbal Rating Scale (VRS) and 5-point VRS pain score for postoperative pain, shoulder pain, site of the most severe pain, and analgesic requirements.”
Habib et al. [13]	“Patients were randomized using a computer-generated random sequence to receive a lidocaine patch or placebo at the end of surgery”	“Patients were randomized using a computer-generated random sequence to receive a lidocaine patch or placebo at the end of surgery.” “The randomization was placed in a sealed opaque envelope and given to the surgeon at the end of the surgery.”	“Neither the patient nor the study personnel were aware of the patient’s group. The surgeon was not involved in any aspect of the data collection.”	“Dressing change was done after completion of the 24 h data collection by a member of the surgical team, who was not involved with the study.” “Data were collected by study personnel unaware of the patients’ randomization”	“Seventy-one patients were enrolled. One patient was lost to follow-up.”	“The primary outcome measure was the verbal rating score for pain at rest and after coughing (11-point verbal rating scale, 0 = no pain, 10 = worst possible pain). Other data collected included postoperative morphine consumption, sedation scores (modified Ramsay score), ² pruritus, and nausea scores (11-point verbal rating scale, 0 = no pruritus/nausea, 10 = worst possible pruritus/nausea).”

Providers and Systems (HCAHPS) in the pay-for-performance model currently used by the Centers for Medicare and Medicaid Services [18].

Conclusions

Future studies are needed examining the use of transdermal lidocaine for specific procedural pain indications, such as placement or removal of chest tubes, extracorporeal membrane oxygenation (ECMO) cannula placement, or dressing changes. It is unlikely given the effect sizes observed in this review and overall lack of difference in opioid consumption that additional perioperative studies in laparoscopic or open abdominal surgery would provide new information.

This review has some limitations. First, there may be unpublished studies or studies only available on other search engines that we did not find in our searches, and these are more likely to be negative studies. Second, despite using two different authors to perform literature searches and using two search engines for the searches, we might have missed some studies that used terminology not detected in our search queries.

In conclusion, transdermal lidocaine may have a limited role in reducing perioperative pain but the magnitude of the improvement is likely small and has not thus far been associated with a reduction in opioid consumption or other patient-centered outcomes.

Funding Information Departmental funds only.

Compliance with Ethical Standards

Conflict of Interest The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. *MMWR Morb Mortal Wkly Rep*. 2017;66(10):265–9.
2. Bremer G, Ekmanner S, et al. Xylocaine; a new local anaesthetic. *Br Dent J*. 1948;85(12):278–81.
3. Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. *J Pain Symptom Manage*. 2017;53(3):614–29. **Provides good summary of available modalities used as topical treatments.**
4. Liu SS, Lin Y. Local Anesthetics. In: Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, editors. *clinical anesthesia*. 6th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2009. p. 531–48.
5. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. *Drugs*. 2004;64(9):937–47. **Provides important details about how transdermal lidocaine works in neuropathic pain.**
6. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
7. Lau LL, Li CY, Lee A, Chan SK. The use of 5% lidocaine medicated plaster for acute postoperative pain after gynecological surgery: a pilot randomized controlled feasibility trial. *Medicine (Baltimore)*. 2018;97(39):e12582.
8. Lee W, Hahn K, Hur J, Kim Y. Effect of topical lidocaine patch on postoperative pain management in laparoscopic appendectomy: a randomized, double-blind, prospective study. *J Laparoendosc Adv Surg Tech A*. 2018;28(9):1061–7.
9. Hong JM, Lee HJ, Cho AR, et al. Pretreatment with 5% lidocaine patch reduces cannula-induced and propofol-induced pain: a randomized, double-blind, placebo-controlled study. *Korean J Anesthesiol*. 2016;69(5):468–73.
10. Vrooman B, Kapural L, Sarwar S, et al. Lidocaine 5% patch for treatment of acute pain after robotic cardiac surgery and prevention of persistent incisional pain: a randomized, placebo-controlled, double-blind trial. *Pain Med*. 2015;16(8):1610–21. **This study was well designed and executed.**
11. Elhafz AA, Elgebaly AS, Bassuoni AS, El Dabaa AA. Is lidocaine patch as effective as intravenous lidocaine in pain and illus reduction after laparoscopic colorectal surgery? A randomized clinical trial. *Anesth Essays Res*. 2012;6(2):140–6.
12. Kwon YS, Kim JB, Jung HJ, et al. Treatment for postoperative wound pain in gynecologic laparoscopic surgery: topical lidocaine patches. *J Laparoendosc Adv Surg Tech A*. 2012;22(7):668–73.
13. Habib AS, Polascik TJ, Weizer AZ, et al. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. *Anesth Analg*. 2009;108(6):1950–3.
14. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328(7454):1490.
15. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
16. Bai Y, Miller T, Tan M, Law LS, Gan TJ. Lidocaine patch for acute pain management: a meta-analysis of prospective controlled trials. *Curr Med Res Opin*. 2015;31(3):575–81.
17. Mazurenko O, Collum T, Ferdinand A, Menachemi N. Predictors of hospital patient satisfaction as measured by HCAHPS: a systematic review. *J Healthc Manag*. 2017;62(4):272–83.
18. Stanowski AC, Simpson K, White A. Pay for performance: are hospitals becoming more efficient in improving their patient experience? *J Healthc Manag*. 2015;60(4):268–85.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.